J.B. Hunt Transport Services, Inc. (JBHT)

J.B. Hunt is trading in the middle of its 52-week range, but it sits below its 50-day and 200-day moving averages ($235.56 and $246.85), and the analysts who cover it are still largely positive. The stock closed at $227.66 on November 11, 2026, 3.35% below its 50-day SMA and 7.77% below its 200-day SMA. CleaRank rates it Hold with a score of 57/100, more cautious than the Buy consensus among Wall Street analysts. The gap between the two views comes down to the trend, which is weak, against earnings, revenue growth and analyst targets, which are firm. For an investor, the question is whether the company's growth can carry the stock back above its long-term averages.

J.B. Hunt beat its EPS estimate in 7 of the last 8 reports, and the share price fell in the first session after 3 of those 7 beats. The October 15, 2026 report came in at $1.82 against a $1.81 estimate, a 0.55% beat, yet the stock fell 2.78% in the first session afterward. The July 15, 2026 report produced a 9.77% beat and an 8.01% gain the next session, so the market reacts to more than the headline beat. Over the eight reports, the share price was higher in the first session after four of them and lower after four.

The price is below both the 50-day SMA of $235.56 and the 200-day SMA of $246.85, and the 50-day SMA itself sits 4.57% below the 200-day SMA. The stock is 17.50% lower over three months and 4.26% lower over six, even though it is 35.49% higher over one year. The one-year gain is a reminder that the stock recovered strongly from its 52-week low of $157.82 before losing ground in the most recent months. The MACD line is negative and the 14-day RSI of 49.8 is in the neutral zone, which means momentum has not yet turned in either direction.

Revenue grew 19.37% in the latest quarter compared with the same quarter a year earlier, which is 7.7 percentage points faster than the sector median of 11.7%. Net profit margin is 5.1% and return on equity is 18.77%, above the sector median of 17.8%. The debt-to-equity ratio is 0.40. The trailing P/E of 32.05 is 60.3% below the sector median of 34.0, and the price-to-sales ratio of 1.59 compares with a sector median of 4.0. That is why CleaRank describes the valuation as broadly in line with peers while the stock's price-to-sales figure looks much lower than the sector.

Of the 24 analysts with a current rating, 15 rate the stock buy or strong buy, 7 hold it and 2 sell it. Three months earlier, 14 of 24 were buy ratings. On October 16, 2026, Citigroup and UBS kept Neutral ratings, while Stephens & Co., Wells Fargo, JP Morgan and Evercore ISI kept Overweight or Outperform ratings. The insider record is less encouraging: the insider sales total $14.0M across 25 sales, against one open-market purchase worth $162K over the last 18 months.

The base case is that the stock stays in a range below its 50-day and 200-day moving averages ($235.56 and $246.85) until either earnings growth or the price itself forces a change. Analysts expect earnings per share to rise 18.5% this fiscal year, to $7.25, and a further 35.8% next year, to $9.85. That is a strong profile, but the price has not yet reflected it, and the trailing P/E of 32.05 is roughly in line with the sector median of 34.0. If the company keeps beating estimates and revenue growth holds near the latest 19.37%, the stock has room to close the gap to the 50-day SMA and then the 200-day SMA. The median analyst target is $285.00, with a range from $187.00 to $330.00. A weaker outcome would follow from a miss on earnings or a fall below the 20-day EMA, which would put the lower support at $157.82 back in view. Simulations from past volatility are not forecasts; the stock's 30-day standard deviation of daily returns is 1.88%.

Support sits first at the 20-day EMA, $225.99, which the price is only just above. Below that, the 52-week low of $157.82 is the next floor, a level the stock has not revisited since its low point in the trailing year. On the upside, the 50-day SMA at $235.56 is the first resistance and the price has to clear it to shift the trend. The 200-day SMA at $246.85 is the second hurdle, and the 52-week high of $299.76 is the furthest reference point above the price.